View Older Stories View More Recent Stories
-
Abbvie (ABBV) PT Raised to $215 at Cantor Fitzgerald
-
AbbVie invests $195 million in US manufacturing facility expansion
-
Piper Sandler Assumes Abbvie (ABBV) at Overweight
-
Buy this U.S. large-cap biopharma stock: JPMorgan
-
Bernstein Reiterates Market Perform Rating on Abbvie (ABBV)
-
Abbvie (ABBV) PT Raised to $227 at Guggenheim
-
Trump Posts Letters to Regeneron, Merck, AstraZeneca, GSK, Pfizer, Novo Nordisk, Amgen, Bristol-Myears, AbbVie, Novartis, Gilead, J&J on Truth Social
-
AbbVie (ABBV) Tops Q2 EPS by 1c; raises guidance
-
Stocks expected to have increasing option volume: ABBV CMCSA BMY RBLX CI CVS K BIIB NCLH ARM MSTR PPC
-
AbbVie earnings preview Q2: set for flat quarter with guidance, M&A in focus
-
AbbVie (ABBV) call put ratio 2.3 calls to 1 put with a focus on January 230 calls into quarter results
-
AbbVie licenses cancer drug ISB 2001 from IGI for up to $1.925 billion
-
AbbVie licenses multiple myeloma drug from IGI for $700 million upfront
-
JPMorgan Reiterates Overweight Rating on Abbvie (ABBV)
-
AbbVie (ABBV) Issues Q2 and FY25 Guidance
-
Morgan Stanley on Abbvie (ABBV) Buying Capstan: 'We view this acquisition as an incremental positive'
-
AbbVie (ABBV) to Acquire Capstan Therapeutics for $2.1 Billion
-
AbbVie (ABBV) Announces FDA's Acceptance of Allergan's Aesthetics Premarket Approval Application for SKINVIVE by JUVÉDERM
-
AbbVie (ABBV) Declares $1.64 Quarterly Dividend; 3.5% Yield
-
AbbVie (ABBV) Announces New Data Demonstrating Atogepant Achieves Superiority Across All Endpoints in Phase 3 Head-to-Head Study Compared to Topiramate for Migraine Prevention
-
Trump Administration Said To Consider Crackdown On Pharma Ads - Bloomberg
-
AbbVie (ABBV) Provides Update on VERONA Trial for Newly Diagnosed Higher-Risk Myelodysplastic Syndromes
-
Sens. Sanders and King Co-Sponsor Bill to End Pharma Ads to Consumers -- WSJ
-
AbbVie (ABBV): U.S. FDA Approves Expanded Indication for MAVYRET as First and Only Treatment for People with Acute Hepatitis C Virus
-
Abbvie (ABBV) PT Lowered to $170 at Berenberg
-
AbbVie (ABBV) Announces FDA Approval of EMRELIS for Adults With Previously Treated Advanced Non-Small Cell Lung Cancer With High c-Met Protein Overexpression
-
AbbVie, Merck cut to Neutral at Citi
-
AbbVie (ABBV) and ADARx Pharmaceuticals Enter Collaboration and License Option Agreement to Develop Next-Generation siRNA Therapies Across Multiple Therapeutic Areas
-
Citi Downgrades Abbvie (ABBV) to Neutral
-
AbbVie (ABBV) call put ratio 1.3 calls to 1 put on active volume of 34K contracts
-
What is the impact of U.S. tariffs on biopharma sector?
-
Abbvie (ABBV) PT Raised to $216 at Guggenheim
-
AbbVie (ABBV) Reports RINVOQ Received FDA Approval for Giant Cell Arteritis (GCA)
-
HSBC cuts biotech stocks: Eli Lilly lowered to Reduce
-
BMO Capital Reiterates Outperform Rating on Abbvie (ABBV)
-
AbbVie (ABBV) EPS Beats Consensus, Updates Guidance
-
AbbVie set to report Q1 results: Focus on Skyrizi, Rinvoq and Part D impact
-
AbbVie (ABBV) call put ratio 1.5 calls to 1 put with a focus on May 182.50
-
AbbVie (ABBV) Submits Biologics License Application to U.S. FDA for TrenibotulinumtoxinE
-
AbbVie (ABBV) call put ratio 1.7 calls to 1 put into quarter results
-
Bernstein SocGen Group Reiterates Market Perform Rating on Abbvie (ABBV)
-
Cantor Fitzgerald Starts Abbvie (ABBV) at Overweight
-
Pharma stocks slide after Trump signals tariffs on sector
-
Goldman Sachs Assumes Abbvie (ABBV) at Neutral
-
AbbVie (ABBV) issues updated guidance
-
Bernstein Assesses U.S. Biopharma Stocks Amid Tariff Risks
-
Truist Weighs In on Obesity: 'Catalyst-Rich 2025 Ahead in a Growing Competitive Landscape'
-
Genmab (GMAB) to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc. (ABBV)
-
Erste Group Upgrades Abbvie (ABBV) to Buy (Friday pre-market)
-
Cantor Fitzgerald says 15% of biotech companies down 40% or more
